Latest period
$31.42B
YoY change
+6.5%
5Y CAGR
+23.2%
Peak year (2025)
$31.26B
Latest annual
$31.26B
Total Equity history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: $31.26B
Total Equity growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: +6.5%
Total Equity history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| 2025 | $31.26B | +6.5% | +$1.90B | ||
| 2024 | $29.35B | +13.0% | +$3.38B | ||
| 2023 | $25.97B | +14.6% | +$3.31B | ||
| 2022 | $22.66B | +20.8% | +$3.90B | ||
| 2021 | $18.77B | +70.2% | +$7.74B | ||
| 2020 | $11.03B | -0.6% | −$64.40M | ||
| 2019 | $11.09B | +26.6% | +$2.33B | ||
| 2018 | $8.76B | +42.5% | +$2.61B | ||
| 2017 | $6.14B | +38.1% | +$1.69B | ||
| 2016 | $4.45B | +21.7% | +$794.41M | ||
| 2015 | $3.65B | +43.8% | +$1.11B | ||
| 2014 | $2.54B | +30.2% | +$590.25M | ||
| 2013 | $1.95B | +56.7% | +$706.69M | ||
| 2012 | $1.25B | +156.4% | +$759.65M | ||
| 2011 | $485.73M | -8.0% | −$42.08M | ||
| 2010 | $527.82M | +33.0% | +$131.05M | ||
| 2009 | $396.76M | -5.3% | −$22.09M | ||
| 2008 | $418.85M | -9.0% | −$41.41M | ||
| 2007 | $460.27M | +112.5% | +$243.64M | ||
| 2006 | $216.62M | +90.0% | +$102.62M | ||
| 2005 | $114.00M | -37.5% | −$68.54M | ||
| 2004 | $182.54M | +32.6% | +$44.90M | ||
| 2003 | $137.64M | -5.7% | −$8.34M | ||
| 2002 | $145.98M | -45.2% | −$120.37M | ||
| 2001 | $266.36M | +46.2% | +$84.22M | ||
| 2000 | $182.13M | +66.3% | +$72.63M | ||
| 1999 | $109.50M | -16.5% | −$21.70M | ||
| 1998 | $131.20M | -5.5% | −$7.70M | ||
| 1997 | $138.90M | +29.9% | +$32.00M | ||
| 1996 | $106.90M | +57.4% | +$39.00M | ||
| 1995 | $67.90M | +1.2% | +$800.00K | ||
| 1994 | $67.10M | -31.8% | −$31.30M | ||
| 1993 | $98.40M | +12.8% | +$11.20M | ||
| 1992 | $87.20M | -17.9% | −$19.00M | ||
| 1991 | $106.20M | +770.5% | +$94.00M | ||
| 1990 | $12.20M | — | — |
- 2025$31.26B+6.5%
- 2024$29.35B+13.0%
- 2023$25.97B+14.6%
- 2022$22.66B+20.8%
- 2021$18.77B+70.2%
- 2020$11.03B-0.6%
- 2019$11.09B+26.6%
- 2018$8.76B+42.5%
- 2017$6.14B+38.1%
- 2016$4.45B+21.7%
- 2015$3.65B+43.8%
- 2014$2.54B+30.2%
- 2013$1.95B+56.7%
- 2012$1.25B+156.4%
- 2011$485.73M-8.0%
- 2010$527.82M+33.0%
- 2009$396.76M-5.3%
- 2008$418.85M-9.0%
- 2007$460.27M+112.5%
- 2006$216.62M+90.0%
- 2005$114.00M-37.5%
- 2004$182.54M+32.6%
- 2003$137.64M-5.7%
- 2002$145.98M-45.2%
- 2001$266.36M+46.2%
- 2000$182.13M+66.3%
- 1999$109.50M-16.5%
- 1998$131.20M-5.5%
- 1997$138.90M+29.9%
- 1996$106.90M+57.4%
- 1995$67.90M+1.2%
- 1994$67.10M-31.8%
- 1993$98.40M+12.8%
- 1992$87.20M-17.9%
- 1991$106.20M+770.5%
- 1990$12.20M—
Total Equity values are taken from Regeneron Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported total equity is $31.42B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Regeneron Pharmaceuticals (REGN) most recent annual total equity stands at $31.26B (2025) – grew 6.5% year-over-year.
Through 2020–2025 (5 years), Regeneron Pharmaceuticals total equity delivered a +23.2% annualised rate; sustaining 5 straight years of year-over-year growth.
2025 marks the peak total equity at $31.26B, with the historical low of $12.20M recorded in 1990.
Regeneron Pharmaceuticals Total Equity by Year
Regeneron Pharmaceuticals Total Equity 2025: $31.26B
Regeneron Pharmaceuticals total equity in 2025 was $31.26B, grew 6.5% from 2024. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Total Equity 2024: $29.35B
2024's total equity for Regeneron Pharmaceuticals came in at $29.35B, grew 13.0% from 2023.
Regeneron Pharmaceuticals Total Equity 2023: $25.97B
Regeneron Pharmaceuticals posted total equity of $25.97B in 2023, grew 14.6% from 2022.
Regeneron Pharmaceuticals Total Equity 2022: $22.66B
In 2022, Regeneron Pharmaceuticals reported total equity of $22.66B, grew 20.8% from 2021.
Regeneron Pharmaceuticals Total Equity 2021: $18.77B
Regeneron Pharmaceuticals total equity in 2021 was $18.77B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Total Equity
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation